Abeona Therapeutics Inc. (NASDAQ:ABEO) shares traded down 5.2% during trading on Friday . The stock traded as low as $3.43 and last traded at $3.44, with a volume of 134,372 shares traded. The stock had previously closed at $3.63.

Several research analysts have commented on the stock. FBR & Co reaffirmed a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research note on Sunday, May 22nd. Zacks Investment Research lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 4th. Maxim Group reaffirmed a “buy” rating and set a $6.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, May 17th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and set a $17.00 price objective on shares of Abeona Therapeutics in a research note on Wednesday, May 18th.

The company’s market capitalization is $113.80 million. The stock’s 50 day moving average price is $2.59 and its 200 day moving average price is $2.65.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.04. On average, equities research analysts predict that Abeona Therapeutics Inc. will post ($0.66) EPS for the current fiscal year.

An institutional investor recently raised its position in Abeona Therapeutics stock. Royce & Associates LLC raised its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned approximately 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent filing with the SEC.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.